Evaluation of effects of Covexir(R) on the immune system in healthy volunteers

Evaluation of effects of Covexir(R) capsule on the immune system in healthy volunteers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180103038199N13

Enrollment

Registered

2023-02-28

Start date

2023-04-04

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers.

Interventions

Intervention 1: Intervention group: Healthy volunteers receiving Covexir at a dose of 350 mg once daily for 30 days. Intervention 2: Control group: Healthy volunteers receiving placebo capsules of the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 18 years old Healthy volunteers (Confirmed by history, physical examination and routine blood tests) Consent to admission to the study Three injections of the inactivated Covid-19 vaccines and at least two months have passed since the last injection. Not being infected with Covid-19 by using a rapid corona test and evaluating clinical symptoms.

Exclusion criteria

Exclusion criteria: Having any diseases Taking other medications Taking any herbal products and supplements Taking Covexir (R) within the previous 6 months

Design outcomes

Primary

Measure	Time frame
Evaluation of parameters related to the immune system (including hs-CRP level). Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.	—

Secondary

Measure	Time frame
Immunoglobulin-E level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-A level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-M level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-G level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-D level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in CBC diff level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Alanine transaminase (ALT) level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Aspartate transaminase (AST) level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;BUN level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Creatinine level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Interleukin-6 level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Interleukin-10 level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;TNF-a level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.	—

Measure

Time frame

Immunoglobulin-E level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-A level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-M level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-G level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Immunoglobulin-D level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in CBC diff level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Alanine transaminase (ALT) level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Aspartate transaminase (AST) level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;BUN level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Creatinine level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Interleukin-6 level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Interleukin-10 level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;TNF-a level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Reza Askari

Mashhad University of Medical Sciences

askariv941@mums.ac.ir+98 51 3800 2264

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026